BACKGROUND: From 2005 through 2007, Seattle health care providers identified cases of primary multiclass drug-resistant (MDR) HIV-1 with common patterns of resistance to antiretrovirals (ARVs). Through surveillance activities and genetic analysis, the local Health Department and the University of Washington identified phylogenetically linked cases among ARV treatment-naive and -experienced individuals. METHODS: HIV-1 pol nucleotide consensus sequences submitted to the University of Washington Clinical Virology Laboratory were assessed for phylogenetically related MDR HIV. Demographic and clinical data collected included HIV diagnosis date, ARV history, and laboratory results. RESULTS: Seven ARV-naive men had phylogenetically linked MDR strains with resistance to most ARVs; these were linked to 2 ARV-experienced men. All 9 men reported methamphetamine use and multiple anonymous male partners. Primary transmissions were diagnosed for more than a 2-year period, 2005-2007. Three, including the 2 ARV-experienced men, were prescribed ARVs. CONCLUSIONS: This cluster of 9 men with phylogenetically related highly drug-resistant MDR HIV strains and common risk factors but without reported direct epidemiologic links may have important implications to public health. This cluster demonstrates the importance of primary resistance testing and of collaboration between the public and private medical community in identifying MDR outbreaks. Public health interventions and surveillance are needed to reduce transmission of MDR HIV-1.
BACKGROUND: From 2005 through 2007, Seattle health care providers identified cases of primary multiclass drug-resistant (MDR) HIV-1 with common patterns of resistance to antiretrovirals (ARVs). Through surveillance activities and genetic analysis, the local Health Department and the University of Washington identified phylogenetically linked cases among ARV treatment-naive and -experienced individuals. METHODS:HIV-1 pol nucleotide consensus sequences submitted to the University of Washington Clinical Virology Laboratory were assessed for phylogenetically related MDR HIV. Demographic and clinical data collected included HIV diagnosis date, ARV history, and laboratory results. RESULTS: Seven ARV-naive men had phylogenetically linked MDR strains with resistance to most ARVs; these were linked to 2 ARV-experienced men. All 9 men reported methamphetamine use and multiple anonymous male partners. Primary transmissions were diagnosed for more than a 2-year period, 2005-2007. Three, including the 2 ARV-experienced men, were prescribed ARVs. CONCLUSIONS: This cluster of 9 men with phylogenetically related highly drug-resistant MDR HIV strains and common risk factors but without reported direct epidemiologic links may have important implications to public health. This cluster demonstrates the importance of primary resistance testing and of collaboration between the public and private medical community in identifying MDR outbreaks. Public health interventions and surveillance are needed to reduce transmission of MDR HIV-1.
Authors: Michael W Plankey; David G Ostrow; Ron Stall; Christopher Cox; Xiuhong Li; James A Peck; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Andrew J Leigh Brown; Simon D W Frost; W Christopher Mathews; Keith Dawson; Nicholas S Hellmann; Eric S Daar; Douglas D Richman; Susan J Little Journal: J Infect Dis Date: 2003-01-29 Impact factor: 5.226
Authors: Carmen de Mendoza; Carmen Rodriguez; Angélica Corral; Jorge del Romero; Oscar Gallego; Vincent Soriano Journal: Clin Infect Dis Date: 2004-09-27 Impact factor: 9.079
Authors: Krishnan Bhaskaran; Deenan Pillay; A Sarah Walker; Martin Fisher; David Hawkins; Richard Gilson; Ken McLean; Kholoud Porter Journal: AIDS Date: 2004-07-02 Impact factor: 4.177
Authors: Deenan Pillay; Krishnan Bhaskaran; Suzanne Jurriaans; Maria Prins; Bernard Masquelier; Francois Dabis; Robert Gifford; Claus Nielsen; Court Pedersen; Claudia Balotta; Giovanni Rezza; Marta Ortiz; Carmen de Mendoza; Claudia Kücherer; Gabriele Poggensee; John Gill; Kholoud Porter Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Dana K Pasquale; Irene A Doherty; Lynne A Sampson; Stephane Hué; Peter A Leone; Joseph Sebastian; Sue L Ledford; Joseph J Eron; William C Miller; Ann M Dennis Journal: J Acquir Immune Defic Syndr Date: 2018-08-01 Impact factor: 3.731
Authors: Nicole E Alexander; Philip A Chan; Tanya O Rogo; Zoanne Parillo; Carola A Browning; Brittany S Isabell; Casandra Calcione; Sutopa Chowdhury; Peter Simon; Rami Kantor Journal: Med Health R I Date: 2012-08
Authors: Martin Stürmer; Katrin Zimmermann; Carlos Fritzsche; Emil Reisinger; Gottfried Doelken; Annemarie Berger; Hans W Doerr; Josef Eberle; Lutz G Gürtler Journal: Med Microbiol Immunol Date: 2010-03-09 Impact factor: 3.402
Authors: George K Hightower; Susanne J May; Josué Pérez-Santiago; Mary E Pacold; Gabriel A Wagner; Susan J Little; Douglas D Richman; Sanjay R Mehta; Davey M Smith; Sergei L Kosakovsky Pond Journal: PLoS One Date: 2013-06-28 Impact factor: 3.240
Authors: Randall J Nett; Jared L Bartschi; Giovanina M Ellis; David M Hachey; Lisa M Frenkel; J Clay Roscoe; Kris K Carter; Christine G Hahn Journal: Emerg Infect Dis Date: 2010-11 Impact factor: 6.883
Authors: Vladimir Novitsky; Hermann Bussmann; Andrew Logan; Sikhulile Moyo; Erik van Widenfelt; Lillian Okui; Mompati Mmalane; Jeannie Baca; Lauren Buck; Eleanor Phillips; David Tim; Mary Fran McLane; Quanhong Lei; Rui Wang; Joseph Makhema; Shahin Lockman; Victor DeGruttola; M Essex Journal: PLoS One Date: 2013-12-11 Impact factor: 3.240